시장보고서
상품코드
1485055

광선각화증 치료 시장 - 세계 산업 규모, 점유율, 동향, 기회, 예측, 치료법별, 약물 유형별, 최종 사용자별, 지역별, 경쟁사별(2019-2029년)

Actinic Keratosis Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Therapy, By Drug Class, By End User, By Region and Competition, 2019-2029F

발행일: | 리서치사: TechSci Research | 페이지 정보: 영문 182 Pages | 배송안내 : 2-3일 (영업일 기준)

    
    
    


■ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

광선각화증 치료제 세계 시장은 2023년 68억 2,000만 달러로 평가되었고, 2029년까지 예측 기간 동안 4.25%의 연평균 복합 성장률(CAGR)로 꾸준히 성장할 것으로 예상됩니다.

광선각화증(AK)은 유해한 자외선(UV)에 장기간 노출되어 발생하는 흔한 피부 질환입니다. 피부에 거칠고 비늘 모양의 반점이 생기는 것이 특징이며, 방치하면 피부암으로 발전할 수 있습니다. 피부 건강에 대한 인식이 높아지고 고령화 인구가 증가함에 따라 세계 광선각화증 치료 시장은 최근 몇 년동안 괄목할 만한 성장을 거듭하고 있습니다. 세계 인구의 고령화에 따라 광선각화증 유병률이 증가하고 있습니다. 특히 베이비붐 세대는 평생 동안 햇빛에 장시간 노출되기 때문에 AK에 더 취약합니다. 피부 건강, 자외선 차단 및 광선각화증과 관련된 위험에 대한 인식이 높아짐에 따라 점점 더 많은 사람들이 치료 및 예방 조치를 찾고 있습니다. 지속적인 연구 개발 노력으로 보다 효과적인 새로운 치료법이 개발되어 시장 성장을 더욱 촉진하고 있습니다. 국소 치료는 종종 광선각화증에 대한 첫 번째 방어선입니다. 이러한 치료제에는 5-플루오로우라실(5-FU), 이미키모도, 디클로페낙과 같은 성분을 함유한 크림과 젤이 포함됩니다. 이들 약제는 전암성 피부 세포를 표적으로 삼아 제거함으로써 효과를 발휘합니다. 냉동 요법은 액체 질소를 사용하여 환부의 피부를 동결시키는 방법입니다. 이 치료법은 단시간에 비용 효율적이며, 고립된 AK 병변에 주로 사용됩니다. 광역학 요법(PDT)은 광과민제를 환부 피부에 도포하고 특정 파장의 빛을 조사하는 것입니다. 이를 통해 광감작제가 활성화되어 AK 세포를 선택적으로 파괴합니다. 레이저 치료는 고에너지의 빛을 이용해 비정상적인 피부 세포를 겨냥하여 제거합니다. 레이저 치료는 심각한 AK 병변이나 광범위한 AK 병변에 효과적입니다. 경우에 따라, 특히 피부암이 의심되는 경우, 해당 부위를 외과적으로 절제해야 할 수도 있습니다. 이를 통해 잠재적인 암세포를 완전히 제거할 수 있습니다.

시장 개요
예측 기간 2025-2029년
시장 규모 : 2023년 68억 2,000만 달러
시장 규모 : 2029년 87억 8,000만 달러
CAGR : 2024-2029년 4.25%
급성장 부문 외과 수술
최대 시장 북미

시장 성장 촉진요인

광선각화증 발생률 증가

고령화 인구의 확대

주요 시장 과제

제한적인 인지도

높은 치료비

제한적인 치료 옵션

주요 시장 동향

기술의 발전

목차

제1장 개요

제2장 조사 방법

제3장 주요 요약

제4장 세계의 광선각화증 치료 시장 전망

  • 시장 규모와 예측
    • 금액별
  • 시장 점유율과 예측
    • 치료법(국소 요법, 수술 요법, 광선 역학 요법)
    • 약제 클래스별(뉴클레오티드 대사 억제제, NSAID, 면역 반응 조절제, 광증강제, 기타)
    • 최종사용자별(병원 및 진료소, 외래 진료 센터, 기타)
    • 지역별
    • 기업별(2023년)
  • 시장 맵
    • 요법 별
    • 약제 클래스별
    • 최종사용자별
    • 지역별

제5장 아시아태평양의 광선각화증 치료 시장 전망

  • 시장 규모와 예측
    • 금액별
  • 시장 점유율과 예측
    • 요법 별
    • 약제 클래스별
    • 최종사용자별
    • 국가별
  • 아시아태평양 : 국가별 분석
    • 중국
    • 인도
    • 호주
    • 일본
    • 한국

제6장 유럽의 광선각화증 치료 시장 전망

  • 시장 규모와 예측
    • 금액별
  • 시장 점유율과 예측
    • 요법 별
    • 약제 클래스별
    • 최종사용자별
    • 국가별
  • 유럽 : 국가별 분석
    • 프랑스
    • 독일
    • 스페인
    • 이탈리아
    • 영국

제7장 북미의 광선각화증 치료 시장 전망

  • 시장 규모와 예측
    • 금액별
  • 시장 점유율과 예측
    • 요법 별
    • 약제 클래스별
    • 최종사용자별
    • 국가별
  • 북미 : 국가별 분석
    • 미국
    • 멕시코
    • 캐나다

제8장 남미의 광선각화증 치료 시장 전망

  • 시장 규모와 예측
    • 금액별
  • 시장 점유율과 예측
    • 요법 별
    • 약제 클래스별
    • 최종사용자별
    • 국가별
  • 남미 : 국가별 분석
    • 브라질
    • 아르헨티나
    • 콜롬비아

제9장 중동 및 아프리카의 광선각화증 치료 시장 전망

  • 시장 규모와 예측
    • 금액별
  • 시장 점유율과 예측
    • 요법 별
    • 약제 클래스별
    • 최종사용자별
    • 국가별
  • 중동 및 아프리카 : 국가별 분석
    • 남아프리카공화국
    • 사우디아라비아
    • 아랍에미리트(UAE)

제10장 시장 역학

  • 성장 촉진요인
  • 과제

제11장 시장 동향과 발전

  • 최근 동향
  • 제품 출시
  • 인수합병(M&A)

제12장 세계의 광선각화증 치료 시장 : SWOT 분석

제13장 Porter의 Five Forces 분석

  • 업계내 경쟁
  • 신규 참여 가능성
  • 공급업체의 힘
  • 고객의 힘
  • 대체품의 위협

제14장 경쟁 구도

  • Almirall S.A.
  • LEO Pharma A/S
  • Sun Pharmaceutical Industries Ltd.
  • Novartis AG
  • GALDERMA SA
  • Ortho Dermatologics(Bausch Health Companies Inc.)
  • BIOFRONTERA AG
  • Hill Dermaceuticals, Inc.

제15장 전략적 제안

제16장 리서치사에 대해 & 면책사항

LSH 24.06.04

Global Actinic Keratosis Treatment Market was valued at USD 6.82 Billion in 2023 and is anticipated to project steady growth in the forecast period with a CAGR of 4.25% through 2029. Actinic keratosis (AK) is a common skin condition caused by prolonged exposure to the sun's harmful ultraviolet (UV) rays. It is characterized by the development of rough, scaly patches on the skin, which, if left untreated, can progress to skin cancer. With increasing awareness about skin health and a growing aging population, the global actinic keratosis treatment market has witnessed significant growth in recent years. As the global population ages, the prevalence of actinic keratosis increases. The baby boomer generation is particularly susceptible to AK due to their prolonged sun exposure over their lifetimes. Greater awareness about skin health, sun protection, and the risks associated with actinic keratosis has prompted more individuals to seek treatment and preventive measures. Ongoing research and development efforts have led to the development of new and more effective treatments, further boosting the market's growth. Topical treatments are often the first line of defense against actinic keratosis. They include creams and gels containing ingredients such as 5-fluorouracil (5-FU), imiquimod, and diclofenac. These medications work by targeting and eliminating precancerous skin cells. Cryotherapy involves freezing the affected skin using liquid nitrogen. This treatment method is quick, cost-effective, and is often used for isolated AK lesions. Photodynamic Therapy (PDT) involves the application of a light-activated photosensitizing agent to the affected skin, followed by exposure to a specific wavelength of light. This activates the agent, which then selectively destroys AK cells. Laser treatment uses high-energy light to target and remove the abnormal skin cells. It is effective for more severe or extensive AK lesions. In some cases, particularly when there is a suspicion of skin cancer, surgical removal of the affected area may be necessary. This ensures that any potential cancerous cells are completely removed.

Market Overview
Forecast Period2025-2029
Market Size 2023USD 6.82 Billion
Market Size 2029USD 8.78 Billion
CAGR 2024-20294.25%
Fastest Growing SegmentSurgery
Largest MarketNorth America

Key Market Drivers

Rising Incidence of Actinic Keratosis

Actinic keratosis (AK), also known as solar keratosis or senile keratosis, is a common skin condition characterized by the development of small, scaly patches on the skin's surface. These lesions are caused by prolonged exposure to ultraviolet (UV) radiation, primarily from the sun. Although AK is considered a precancerous condition, it has the potential to progress into squamous cell carcinoma if left untreated. This threat has driven the demand for effective treatments, contributing to the growth of the global actinic keratosis treatment market. The incidence of actinic keratosis is on the rise worldwide, making it a significant public health concern. The primary factor contributing to this increase is the greater awareness of the dangers of excessive sun exposure and the importance of early detection and treatment. Additionally, the aging population, particularly in developed countries, has further fueled the growth of actinic keratosis cases. As populations age and UV exposure accumulates over time, the likelihood of developing AK and other skin-related conditions, including skin cancers, rises. The connection between AK and squamous cell carcinoma is a major driver of the global actinic keratosis treatment market, as early intervention can prevent the progression to a more severe form of cancer.

Recent years have seen significant advancements in the treatment options available for actinic keratosis. Topical therapies, cryotherapy, photodynamic therapy, and laser treatments have become more effective, with fewer side effects and shorter recovery times. These innovations have spurred the adoption of treatment, further boosting the actinic keratosis treatment market. Public awareness of the risks associated with actinic keratosis and skin cancer has grown substantially. Skin cancer prevention campaigns, as well as regular skin check-ups, have led to earlier diagnoses and subsequent treatment. This heightened awareness has created a greater demand for AK treatment, thereby driving market growth. The global population is aging, especially in developed countries where the prevalence of AK is higher due to a history of sun exposure. As people age, the likelihood of developing actinic keratosis increases. This demographic trend acts as a natural driver for the market, as a growing patient pool seeks treatment.

Innovations in medical technology, such as the development of non-invasive treatment options, have significantly expanded the treatment landscape for AK. Laser therapies, for example, offer targeted and precise removal of affected skin without causing extensive damage to surrounding tissue. Health authorities and regulatory bodies have been instrumental in promoting the safe and effective treatment of actinic keratosis. Their guidelines and approvals for new treatment options have provided both healthcare providers and patients with the assurance of quality care, further driving market growth.

Expanding Aging Population

The global population is experiencing a demographic shift with significant implications for healthcare. One of the most prominent trends in this shift is the increasing number of elderly individuals. According to the World Health Organization (WHO), the proportion of the global population aged 60 and over is expected to double by 2050, reaching approximately 22% of the total population. This trend is observed across the world, with many countries witnessing a surge in the elderly population. Factors contributing to the aging population include increased life expectancy due to advancements in healthcare and a decrease in birth rates in some countries. As a result, healthcare systems are being challenged to provide quality care and effective treatments for age-related conditions, such as actinic keratosis.

Actinic keratosis is a skin condition characterized by the development of small, scaly patches on the skin's surface. These patches are usually rough, dry, and may be red, brown, or skin-colored. They are considered precancerous lesions, and if left untreated, they can progress to squamous cell carcinoma, a type of skin cancer. The primary cause of actinic keratosis is prolonged exposure to ultraviolet (UV) radiation, mainly from the sun. Over time, cumulative sun damage can lead to the development of these lesions. As the aging population continues to grow, the prevalence of actinic keratosis cases is expected to rise due to the cumulative effects of UV exposure over the years.

The expanding aging population has generated a substantial increase in the demand for actinic keratosis treatments. This surge in demand has prompted the growth of the global actinic keratosis treatment market. The pharmaceutical and healthcare industries have responded to the rising demand by developing innovative treatments for actinic keratosis. These treatments include topical creams, cryotherapy, laser therapy, and photodynamic therapy, among others. Increased awareness of the risks associated with sun exposure and regular skin screenings have led to early detection of actinic keratosis. This, in turn, has driven the demand for treatment options, as early intervention can prevent the progression to skin cancer. Governments and healthcare organizations are allocating more resources to address the healthcare needs of an aging population. This includes funding for dermatological services and treatments for age-related skin conditions. Developing countries, where the aging population is also on the rise, are witnessing an expansion of the actinic keratosis treatment market as healthcare infrastructure and access to healthcare services improve.

Key Market Challenges

Limited Awareness

The primary challenges for the actinic keratosis treatment market is the lack of awareness among the general population. Many individuals are unaware of the risks associated with actinic keratosis and may not recognize its symptoms. As a result, a large number of cases go undiagnosed and untreated. To address this issue, public health campaigns and educational initiatives are necessary to raise awareness about actinic keratosis, its risk factors, and the importance of early treatment.

High Treatment Costs

Actinic keratosis treatments can be costly, especially for advanced cases that require multiple sessions of therapy. These high treatment costs can act as a barrier to access for many patients, leading to delayed or inadequate treatment. Pharmaceutical companies and healthcare providers need to work together to make treatments more affordable and accessible, possibly through the development of cost-effective treatment options and increased insurance coverage for actinic keratosis therapy.

Limited Treatment Options

The current treatment options for actinic keratosis are somewhat limited, with common approaches including cryotherapy, topical medications, laser therapy, and photodynamic therapy. While these treatments can be effective, they may not be suitable for all patients. Developing innovative and more targeted therapies is a challenge in the field, but it is essential for improving treatment outcomes and reducing side effects.

Key Market Trends

Technological Advancements

Actinic keratosis (AK), often referred to as solar keratosis or senile keratosis, is a common skin condition caused by prolonged exposure to ultraviolet (UV) radiation from the sun. If left untreated, it can progress into a more serious form of skin cancer known as squamous cell carcinoma. As the prevalence of AK continues to rise due to increasing sun exposure and an aging population, the global market for actinic keratosis treatment is expanding. However, it's not just the growing prevalence of AK that is driving this market; technological advancements are playing a crucial role in the development of more effective and patient-friendly treatments.

The key technological advancements in the AK treatment market is the development of non-invasive therapies. Traditionally, AK lesions were treated with cryotherapy (freezing), curettage (scraping), or topical treatments. While these methods are effective, they can be painful and may lead to scarring. Newer technologies, such as photodynamic therapy (PDT) and laser therapy, offer non-invasive alternatives that target AK lesions with precision, minimizing pain and scarring. PDT, for instance, uses a photosensitizing agent and specific light wavelengths to destroy AK lesions without causing significant damage to surrounding healthy tissue. Advances in topical medications have also greatly improved AK treatment. Prescription creams containing 5-fluorouracil (5-FU), imiquimod, or diclofenac can effectively target and eliminate AK lesions with minimal side effects. These topical treatments are more patient-friendly compared to traditional approaches, and they are increasingly favored by both patients and healthcare providers. Telemedicine and teledermatology have become instrumental in AK diagnosis and treatment. With the advent of smartphones and high-quality imaging technologies, patients can easily send photos of their skin lesions to dermatologists for evaluation. This allows for quicker diagnosis and treatment planning, reducing the need for in-person visits. Additionally, teledermatology has improved follow-up care, ensuring that patients adhere to their treatment regimens. Advancements in understanding the molecular and genetic underpinnings of AK have led to the development of targeted therapies. Medications that specifically target the pathways responsible for AK development have shown promising results. These therapies not only improve treatment efficacy but also reduce side effects, making them more patient-friendly. Accurate diagnosis and assessment of AK lesions are critical for effective treatment. 3D imaging and biopsies have improved the precision of diagnosis, helping healthcare providers identify high-risk lesions that require more aggressive treatment. This technological advance ensures that treatment efforts are appropriately directed.

The combination of these technological advancements has not only improved the patient experience but has also expanded the market for AK treatment. More patients are seeking treatment for AK, and they are increasingly willing to explore newer, less invasive options. As a result, the global market for actinic keratosis treatment is projected to experience significant growth in the coming years. Additionally, increased awareness about the risks of AK and skin cancer has prompted individuals to seek medical advice and treatment at an earlier stage. The role of technology in educating and engaging patients cannot be underestimated. Mobile applications, websites, and telemedicine platforms are now being used to disseminate information and facilitate consultations.

Segmental Insights

Therapy Insights

Based on the category of therapy, Surgery emerged as the dominant player in the global market for Actinic Keratosis Treatment in 2023. Several treatment options are available for actinic keratosis, including topical treatments, cryotherapy, photodynamic therapy, laser therapy, and surgery. While each method has its merits, surgical procedures have stood the test of time as an effective means of treatment. Surgical procedures ensure complete removal of the affected tissue, reducing the risk of recurrence and progression to squamous cell carcinoma. Techniques like Mohs micrographic surgery and excision are highly precise, preserving healthy tissue while eliminating the disease. Surgery often provides immediate results, with improved skin appearance and reduced discomfort for patients. Surgery not only treats actinic keratosis but also improves the overall health and appearance of the skin, making it a favourable option for many patients.

Drug Class Insights

The Nucleoside metabolic inhibitors segment is projected to experience rapid growth during the forecast period. Nucleoside metabolic inhibitors are a class of medications that interfere with the metabolic processes of rapidly dividing cells, making them particularly effective for the treatment of precancerous lesions like actinic keratosis. They work by disrupting the synthesis of DNA and RNA, causing cell death in the affected areas. These medications have demonstrated high success rates in clearing actinic keratosis lesions, reducing the risk of progression to squamous cell carcinoma. Many nucleoside metabolic inhibitors have shorter treatment durations compared to other therapies, making them more convenient for patients. Topical application minimizes the need for surgical procedures, reducing the risk of scarring and infection. Nucleoside metabolic inhibitors can be applied at home, promoting better patient compliance.

Regional Insights

North America emerged as the dominant region in the global Actinic Keratosis Treatment market in 2023, holding the largest market share in terms of value. North America has one of the highest incidence rates of actinic keratosis globally. This high prevalence is attributed to factors like excessive UV exposure, fair skin populations, and an aging demographic. As a result, North America represents a substantial patient pool, contributing significantly to the region's dominance in the actinic keratosis treatment market. The healthcare infrastructure in North America is well-developed and technologically advanced. The region boasts numerous dermatology clinics and healthcare facilities that offer state-of-the-art actinic keratosis treatment options. This includes a wide array of topical therapies, cryotherapy, photodynamic therapy, and surgical excisions.

Key Market Players

Almirall S.A.

LEO Pharma A/S

Sun Pharmaceutical Industries Ltd.

Novartis AG

GALDERMA SA

Ortho Dermatologics (Bausch Health Companies Inc.)

BIOFRONTERA AG

Hill Dermaceuticals, Inc.

Report Scope:

In this report, the Global Actinic Keratosis Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Actinic Keratosis Treatment Market, By Therapy:

    Topical Surgery Photodynamic Therapy

Actinic Keratosis Treatment Market, By Drug Class:

    Nucleoside metabolic inhibitor NSAIDS Immune response modifiers Photoenhancers Others

Actinic Keratosis Treatment Market, By End User:

    Hospitals & Clinics Ambulatory Care Centers Others

Actinic Keratosis Treatment Market, By Region:

    North America

United States

Canada

Mexico

    Europe

France

United Kingdom

Italy

Germany

Spain

    Asia-Pacific

China

India

Japan

Australia

South Korea

    South America

Brazil

Argentina

Colombia

    Middle East & Africa

South Africa

Saudi Arabia

UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Actinic Keratosis Treatment Market.

Available Customizations:

Global Actinic Keratosis Treatment market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Global Actinic Keratosis Treatment Market Outlook

  • 4.1. Market Size & Forecast
    • 4.1.1. By Value
  • 4.2. Market Share & Forecast
    • 4.2.1. By Therapy (Topical, Surgery, Photodynamic Therapy)
    • 4.2.2. By Drug Class (Nucleoside metabolic inhibitor, NSAIDS, Immune response modifiers, Photoenhancers, Others)
    • 4.2.3. By End user (Hospitals & Clinics, Ambulatory Care Centers, Others)
    • 4.2.4. By Region
    • 4.2.5. By Company (2023)
  • 4.3. Market Map
    • 4.3.1. By Therapy
    • 4.3.2. By Drug Class
    • 4.3.3. By End user
    • 4.3.4. By Region

5. Asia Pacific Actinic Keratosis Treatment Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Therapy
    • 5.2.2. By Drug Class
    • 5.2.3. By End user
    • 5.2.4. By Country
  • 5.3. Asia Pacific: Country Analysis
    • 5.3.1. China Actinic Keratosis Treatment Market Outlook
      • 5.3.1.1. Market Size & Forecast
        • 5.3.1.1.1. By Value
      • 5.3.1.2. Market Share & Forecast
        • 5.3.1.2.1. By Therapy
        • 5.3.1.2.2. By Drug Class
        • 5.3.1.2.3. By End user
    • 5.3.2. India Actinic Keratosis Treatment Market Outlook
      • 5.3.2.1. Market Size & Forecast
        • 5.3.2.1.1. By Value
      • 5.3.2.2. Market Share & Forecast
        • 5.3.2.2.1. By Therapy
        • 5.3.2.2.2. By Drug Class
        • 5.3.2.2.3. By End user
    • 5.3.3. Australia Actinic Keratosis Treatment Market Outlook
      • 5.3.3.1. Market Size & Forecast
        • 5.3.3.1.1. By Value
      • 5.3.3.2. Market Share & Forecast
        • 5.3.3.2.1. By Therapy
        • 5.3.3.2.2. By Drug Class
        • 5.3.3.2.3. By End user
    • 5.3.4. Japan Actinic Keratosis Treatment Market Outlook
      • 5.3.4.1. Market Size & Forecast
        • 5.3.4.1.1. By Value
      • 5.3.4.2. Market Share & Forecast
        • 5.3.4.2.1. By Therapy
        • 5.3.4.2.2. By Drug Class
        • 5.3.4.2.3. By End user
    • 5.3.5. South Korea Actinic Keratosis Treatment Market Outlook
      • 5.3.5.1. Market Size & Forecast
        • 5.3.5.1.1. By Value
      • 5.3.5.2. Market Share & Forecast
        • 5.3.5.2.1. By Therapy
        • 5.3.5.2.2. By Drug Class
        • 5.3.5.2.3. By End user

6. Europe Actinic Keratosis Treatment Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Therapy
    • 6.2.2. By Drug Class
    • 6.2.3. By End user
    • 6.2.4. By Country
  • 6.3. Europe: Country Analysis
    • 6.3.1. France Actinic Keratosis Treatment Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Therapy
        • 6.3.1.2.2. By Drug Class
        • 6.3.1.2.3. By End user
    • 6.3.2. Germany Actinic Keratosis Treatment Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Therapy
        • 6.3.2.2.2. By Drug Class
        • 6.3.2.2.3. By End user
    • 6.3.3. Spain Actinic Keratosis Treatment Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Therapy
        • 6.3.3.2.2. By Drug Class
        • 6.3.3.2.3. By End user
    • 6.3.4. Italy Actinic Keratosis Treatment Market Outlook
      • 6.3.4.1. Market Size & Forecast
        • 6.3.4.1.1. By Value
      • 6.3.4.2. Market Share & Forecast
        • 6.3.4.2.1. By Therapy
        • 6.3.4.2.2. By Drug Class
        • 6.3.4.2.3. By End user
    • 6.3.5. United Kingdom Actinic Keratosis Treatment Market Outlook
      • 6.3.5.1. Market Size & Forecast
        • 6.3.5.1.1. By Value
      • 6.3.5.2. Market Share & Forecast
        • 6.3.5.2.1. By Therapy
        • 6.3.5.2.2. By Drug Class
        • 6.3.5.2.3. By End user

7. North America Actinic Keratosis Treatment Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Therapy
    • 7.2.2. By Drug Class
    • 7.2.3. By End user
    • 7.2.4. By Country
  • 7.3. North America: Country Analysis
    • 7.3.1. United States Actinic Keratosis Treatment Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Therapy
        • 7.3.1.2.2. By Drug Class
        • 7.3.1.2.3. By End user
    • 7.3.2. Mexico Actinic Keratosis Treatment Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Therapy
        • 7.3.2.2.2. By Drug Class
        • 7.3.2.2.3. By End user
    • 7.3.3. Canada Actinic Keratosis Treatment Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Therapy
        • 7.3.3.2.2. By Drug Class
        • 7.3.3.2.3. By End user

8. South America Actinic Keratosis Treatment Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Therapy
    • 8.2.2. By Drug Class
    • 8.2.3. By End user
    • 8.2.4. By Country
  • 8.3. South America: Country Analysis
    • 8.3.1. Brazil Actinic Keratosis Treatment Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Therapy
        • 8.3.1.2.2. By Drug Class
        • 8.3.1.2.3. By End user
    • 8.3.2. Argentina Actinic Keratosis Treatment Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Therapy
        • 8.3.2.2.2. By Drug Class
        • 8.3.2.2.3. By End user
    • 8.3.3. Colombia Actinic Keratosis Treatment Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Therapy
        • 8.3.3.2.2. By Drug Class
        • 8.3.3.2.3. By End user

9. Middle East and Africa Actinic Keratosis Treatment Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Therapy
    • 9.2.2. By Drug Class
    • 9.2.3. By End user
    • 9.2.4. By Country
  • 9.3. MEA: Country Analysis
    • 9.3.1. South Africa Actinic Keratosis Treatment Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Therapy
        • 9.3.1.2.2. By Drug Class
        • 9.3.1.2.3. By End user
    • 9.3.2. Saudi Arabia Actinic Keratosis Treatment Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Therapy
        • 9.3.2.2.2. By Drug Class
        • 9.3.2.2.3. By End user
    • 9.3.3. UAE Actinic Keratosis Treatment Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Therapy
        • 9.3.3.2.2. By Drug Class
        • 9.3.3.2.3. By End user

10. Market Dynamics

  • 10.1. Drivers
  • 10.2. Challenges

11. Market Trends & Developments

  • 11.1. Recent Developments
  • 11.2. Product Launches
  • 11.3. Mergers & Acquisitions

12. Global Actinic Keratosis Treatment Market: SWOT Analysis

13. Porter's Five Forces Analysis

  • 13.1. Competition in the Industry
  • 13.2. Potential of New Entrants
  • 13.3. Power of Suppliers
  • 13.4. Power of Customers
  • 13.5. Threat of Substitute Product

14. Competitive Landscape

  • 14.1. Almirall S.A.
    • 14.1.1. Business Overview
    • 14.1.2. Company Snapshot
    • 14.1.3. Product & Services
    • 14.1.4. Financials (In case of listed)
    • 14.1.5. Recent Developments
    • 14.1.6. SWOT Analysis
  • 14.2. LEO Pharma A/S
  • 14.3. Sun Pharmaceutical Industries Ltd.
  • 14.4. Novartis AG
  • 14.5. GALDERMA SA
  • 14.6. Ortho Dermatologics (Bausch Health Companies Inc.)
  • 14.7. BIOFRONTERA AG
  • 14.8. Hill Dermaceuticals, Inc.

15. Strategic Recommendations

16. About Us & Disclaimer

비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제